Patent ID: 7268119

Claim:
A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of the formula (I) which may be a D- or L-nucleotide or nucleoside in combination with a pharmaceutically acceptable carrier: wherein R 1 , R 2 , R 2′ , R 3 , R 3′ , and R 4 are independently H, F, Cl, Br, I, OH, SH, NH 2 , NHOH, NHNH 2 , N 3 , COOH, CN, CONH 2 , C(S)NH 2 , COOR, R, OR, SR, SSR, NHR, or NR 2 , wherein R 2 or R 2′ are not both hydrogen; L is O, S, NH, NR, CY 2 O, CY 2 S, CY 2 NH, CY 2 , CY 2 CY 2 , CY 2 OCY 2 , CY 2 SCY 2 , or CY 2 NHCY 2 , wherein Y is H, F, Cl, Br, alkyl, alkenyl, or alkynyl, and wherein alkyl, alkenyl, and alkynyl may each optionally contain one or more heteroatoms; R 5 is OH, monophosphate, diphosphate, or triphosphate, or a phosphonate, phosphoamidate, or phosphoester thereof; B is a base selected from: wherein dashed lines (---) indicate an optional π bond; X is N, NH, or NR; Z is C-G, O, >C═O, >C═S, or CH-G, wherein if Z is a participant in a π bond then Z is C-G, and when Z is not a participant in a π bond then Z is O, >C═O, >C═S, or CH-G; Z 1 is C-G or CH-G, wherein if Z 1 is a participant in a π bond then Z 1 is C-G, and when Z 1 is not a participant in a π bond then Z 1 is CH-G; Z 2 is C-G or CH-G, wherein if Z 2 is a participant in a π bond then Z 2 is C-G, and when Z 2 is not a participant in a π bond then Z 2 is CH-G; Z 3 is CH or N; Z 4 is C-G, >C═O, >C═S, >C═NH or >C═NR, wherein if Z 4 is a participant in a π bond then Z 4 is C-G, and if Z 4 is not a participant in a π bond then Z 4 is >C═O, >C═S, >C═NH or >C═NR; each G is independently H, F, Cl, Br, I, OH, SH, NH 2 , NHOH, N 3 , COOH, CN, CONH 2 , C(S)NH 2 , C(═NH)NH 2 , R, OR, SR, NHR, or NR 2 ; and each R is independently alkyl, alkenyl, alkynyl, aryl, acyl, or aralkyl, optionally containing one or more heteroatoms; or a pharmaceutically acceptable salt thereof.